Bristol-Myers immunotherapy combo promising in melanoma: study

(Reuters) - A combination of two Bristol-Myers Squibb drugs that help the immune system fight melanoma led to significantly greater tumor shrinkage than treatment with one of the medicines, according to a midstage study presented on Monday.

from

Lilly's psoriatic arthritis drug succeeds in late-stage study

(Reuters) - Eli Lilly and Co said its experimental drug, ixekizumab, was more effective than a placebo in patients with active psoriatic arthritis, in a late-stage trial.

from

Forget the martini lunch, sweatworking mixes business with exercise

NEW YORK (Reuters) - Sweatworking, the growing practice of meeting clients for a walk, a run or a fitness class, is elbowing networking out of bars and restaurants and into boutique fitness studios.

from

China considers ban on infant formula ads

SHANGHAI (Reuters) - China is considering a ban on advertisements for infant milk formula in a bid to tackle low levels of breast feeding, the official Xinhua news agency said on Monday, a potential headache for firms targeting the country's near $18 billion market.

from

Seeking Obamacare alternative, Republicans eye tax credits

WASHINGTON (Reuters) - If the U.S. Supreme Court blows up the tax subsidies at the heart of Obamacare in June, Republicans hope to deliver on their promise to offer an alternative healthcare plan.

from

Soccer idols Zidane and Ronaldo team up in U.N. Ebola fundraiser

LONDON (Thomson Reuters Foundation) - Soccer idols Zinedine Zidane and Ronaldo will lead a star-studded team in a friendly match on Monday aimed at raising money to help Ebola-hit Guinea, Liberia and Sierra Leone.

from

Teva shares slide on generic Copaxone fears

TEL AVIV (Reuters) - Teva Pharmaceutical Industries shares slid five percent on Sunday after U.S. regulators approved a generic version of its top-selling multiple sclerosis drug and amid reports it was mulling a bid for rival Mylan.

from